CEL-SCI (FRA:LSR) Notes Receivable: €0.00 Mil (As of Mar. 2026)


FRA:LSR CEL-SCI Corp FRA:LSR
23 GF Score
Price €0.76
! 2 Warning Signs
View Full Analysis

What is CEL-SCI Notes Receivable?

CEL-SCI FRA:LSR -9.52% 23 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:LSR with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

CEL-SCI's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

CEL-SCI Notes Receivable Historical Data

* Premium members only.

The historical data trend for CEL-SCI's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEL-SCI Notes Receivable Chart

CEL-SCI Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CEL-SCI Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:LSR
23GF Score
CEL-SCI Corp FRA:LSR
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CEL-SCI Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
CEL-SCI (FRA:LSR) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on CEL-SCI and its competitors.
Is CEL-SCI's Notes Receivable too high?
CEL-SCI's current Notes Receivable is €0.00 Mil. Overall, CEL-SCI has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does CEL-SCI's Notes Receivable compare to TRAW and QNCX?
CEL-SCI's Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on CEL-SCI and its competitors. CEL-SCI's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CEL-SCI stock overvalued right now?
CEL-SCI (FRA:LSR) has a current Notes Receivable of €0.00 Mil. The current Notes Receivable is €0.00 Mil. CEL-SCI's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For CEL-SCI (FRA:LSR), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CEL-SCI Business Description

Other Exchanges CVM:USA
Address 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
23GF Score

Get the complete analysis for FRA:LSR

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.76
Price